Table 2.
Analysis of anti-herpesvirus antibody and DNA in MS and controls.
| MS n (%) | Control n (%) | Fisher’s exact Test | ||||
|---|---|---|---|---|---|---|
| Method | Herpesvirus | + | - | + | - | p value |
| ELISA | HCMV | 105 (84.68%) | 19 (15.32%) | 58 (82.86%) | 12 (17.14%) | 0.84 |
| HHV6 | 79 (63.71%) | 45 (36.29%) | 32 (45.71%) | 38 (54.29%) | 0.02 | |
| EBV | 121 (97.58%) | 3 (2.42%) | 65 (92.86%) | 5 (7.14%) | 0.14 | |
| VZV | 109 (87.90%) | 15 (12.10%) | 56 (80.00%) | 14 (20.00%) | 0.15 | |
| qPCR | HCMV | 0 (0.00%) | 124 (100.00%) | 0 (0.00%) | 59 (100.00%) | 1 |
| HHV6 | 1 (0.81%) | 123 (99.19%) | 1 (1.69%) | 58 (98.31%) | 0.54 | |
| EBV | 1 (0.81%) | 123 (99.19%) | 1 (1.69%) | 58 (98.31%) | 0.54 | |
| VZV | 29 (23.39%) | 95 (76.61%) | 13 (22.03%) | 46 (77.97%) | 1 | |
ELISA, enzyme-linked immunosorbent assay; qPCR,ndash; quantitative polymerase chain reaction; HCMV, human cytomegalovirus; HHV6, human herpes virus 6; EBV, Epstein-Barr virus; VZV, varicella zoster virus; n- number of patients; % -percent from total number of patients.